Expert Commentary

Dr. Michael Krychman details new and in-the-pipeline treatment options for vulvovaginal atrophy

Author and Disclosure Information

A better understanding of the physical and anatomic changes during menopause has led to improved treatments for vulvovaginal atrophy (also known as genitourinary syndrome of menopause)



In an audiocast summarizing his Sunday Lunch Talk at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) on May 3, 2015, Dr. Michael L. Krychman discusses new treatment options for vulvar and vaginal atrophy (VVA), including over-the-counter and prescription products and procedures. He emphasizes that a better understanding of the physical and anatomic changes in menopause has led to these improved options.

Dr. Krychman also recommends the use of "genitourinary syndrome of menopause" (GSM), new terminology for VVA suggested by the International Society for the Study of Women's Sexual Health and the North American Menopause Society.1

Among the products Dr. Krychman details are neogyn® Feminine Soothing Cream (neogyn, inc., Switzerland); RepHresh™ Vaginal Gel (Church & Dwight Co., Inc., Princeton, New Jersey); Replens™ Long-Lasting Vaginal Moisturizer (Church & Dwight); silicone- and water-based lubricants (Replens Silky Smooth Lubricant [Church & Dwight]; JuvaGyn® Feminine Moisturizer [neogyn, inc.]); and ospemifene (Osphena®, Shionogi Inc., Florham Park, New Jersey).

Dr. Krychman is interested in a new laser procedure for VVA/GSM, but comments that more study is needed before he can recommend its general use. He also talks about other exciting alternatives in the pipeline.

Next Article:

Estrogen assays need to improve

Related Articles